SEC Tracker
Get the app

Design Therapeutics DSGN

Design Therapeutics reported a net loss of $20.29 million for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $20.29 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.32 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $15.25 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Design Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Alector ALEC public float $115M, Jun 30, 2025
  2. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  3. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  4. Caribou Biosciences CRBU public float $113M, Jun 30, 2025
  5. Protara Therapeutics PRTO public float $112M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.